Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal
10 December 2021 - 11:30PM
AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or
“we”) (NASDAQ: ANPC), a biotechnology company with operations in
China and the United States, announced today its joint technical
paper on novel Cancer Differentiation Analysis (CDA) Technology for
multi-cancer screening with multiple leading medical institutions
was accepted and published online on November 30, 2021 by the
Expert Review of Molecular Diagnostics, a
peer-reviewed international medical journal that has an impact
factor of 5.2.
The title of the published paper is “Development and Evaluation
of Cancer Differentiation Analysis Technology: A Novel
Biophysics-Based Screening Method”. The co-authors of the paper
included several leading medical institutions in China, including
the School of Medicine, Shanghai Jiao Tong University, and
Department of Statistics and Data Management at Children’s Hospital
of Fudan University. The paper reported the mechanism of CDA
technology, as well as an extensive, multi-year, multi-cancer
screening validation work that included a two-stage study design.
This cross-sectional study of CDA testing in the initial stage,
included a routine health checkup involving 75,942 individuals
which was followed by a prospective population-based cohort study
involving 1,957 individuals. The studies concluded that the CDA
test is useful for cancer screening with high specificity and
moderate sensitivity among healthy individuals and continues to lay
both the conceptual and practical foundation for AnPac Bio’s novel
biophysics-based test for cancer screening. Based on results from
the study, the published technical paper also cited a number of
advantages of CDA technology which include its potential
suitability for health screening, estimated cost quite comparable
or lower than that of other screening methods, and its multi-cancer
screening ability for large population.
Dr. Chris Yu, AnPac Bio’s Chairman and CEO commented: “We are
very pleased with the publication of our technical paper on CDA
cancer detection technology by a peer-reviewed international
journal in the field of medicine. The review and subsequent
acceptance of our paper based on the novel and original
biophysics-based CDA cancer detection technology for publication is
very gratifying and indicates what we believe is a positive level
of recognition for this approach. The findings reported in this
study validates the CDA technology and has laid both the conceptual
and practical groundwork for CDA technology to be used in large
population cancer screening.” Dr. Chris Yu further commented: “We
will continue to invest in research and development, and at the
same time, speed up our commercialization process. We believe we
are making solid progress in the class III medical device
registration process with NMPA (for lung cancer assisting in
diagnosis utility), and we now expect to receive the class III
medical device license by late 2022.”
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer
screening and detection, with 150 issued patents as of September
30, 2021. With two certified clinical laboratories in China and one
CLIA and CAP accredited clinical laboratory in the United States,
AnPac Bio performs a suite of cancer screening and detection tests,
including CDA (Cancer Differentiation Analysis), bio-chemical,
immunological, and genomics tests. According to Frost &
Sullivan, AnPac Bio ranked third worldwide among companies offering
next-generation early cancer screening and detection technologies
in terms of the number of clinical samples for cancer screening and
detection, based on approximately 43,980 clinical samples as of
September 30, 2021. AnPac Bio’s CDA technology platform has been
shown in retrospective validation studies to be able to detect the
risk of over 20 different cancer types with high sensitivity and
specificity.
For more information, please
visit: https://www.Anpacbio.com.
For investor and media inquiries, please
contact:
Company:Phil Case, Marketing and Investor RelationsPhone:
+1-267-810-6776 (US)Email: phil_case@AnPacbio.com
Investor Relations:Ascent Investor Relations LLCTina Xiao,
PresidentPhone: +1-917-609-0333
(US)Email: tina.xiao@ascent-ir.com
Safe Harbor Statement
This announcement contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements are made under the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995
and are relating to the Company’s future financial and operating
performance. The Company has attempted to identify forward-looking
statements by terminologies including “believes,” “estimates,”
“anticipates,” “expects,” “plans,” “projects,” “intends,”
“potential,” “target,” “aim,” “predict,” “outlook,” “seek,” “goal”
“objective,” “assume,” “contemplate,” “continue,” “positioned,”
“forecast,” “likely,” “may,” “could,” “might,” “will,” “should,”
“approximately” or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are based on current expectations, assumptions and
uncertainties involving judgments about, among other things, future
economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the Company’s control.
These statements also involve known and unknown risks,
uncertainties and other factors that may cause the Company’s actual
results to be materially different from those expressed or implied
by any forward-looking statement. Known and unknown risks,
uncertainties and other factors include, but are not limited to,
the implementation of our business model and growth strategies;
trends and competition in the cancer screening and detection
market; our expectations regarding demand for and market acceptance
of our cancer screening and detection tests and our ability to
expand our customer base; our ability to obtain and maintain
intellectual property protections for our CDA technology and our
continued research and development to keep pace with technology
developments; our ability to obtain and maintain regulatory
approvals from the NMPA, the FDA and the relevant U.S. states and
have our laboratories certified or accredited by authorities
including the CLIA; our future business development, financial
condition and results of operations and our ability to obtain
financing cost-effectively; potential changes of government
regulations; general economic and business conditions in China and
elsewhere; our ability to hire and maintain key personnel; our
relationship with our major business partners and customers; and
the duration of the coronavirus outbreaks and their potential
adverse impact on the economic conditions and financial markets and
our business and financial performance, such as resulting from
reduced commercial activities due to quarantines and travel
restrictions instituted by China, the U.S. and many other countries
around the world to contain the spread of the virus. Additionally,
all forward-looking statements are subject to the “Risk Factors”
detailed from time to time in the Company’s most recent Annual
Report on Form 20-F and other filings with the U.S. Securities
and Exchange Commission. Because of these and other risks,
uncertainties and assumptions, undue reliance should not be placed
on these forward-looking statements. In addition, these statements
speak only as of the date of this press release and, except as may
be required by law, the Company undertakes no obligation to revise
or update publicly any forward-looking statements for any
reason.
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Apr 2023 to Apr 2024